LLY up +1.88% percent Today $LLY High is at 67.87
Post# of 128
Posted On: 11/10/2014 1:52:19 PM
LLY up +1.88% percent Today $LLY High is at 67.87 and the Low 66.42 with current volume of 1,240,527.
Recent News posted below.
Eli Lilly and Company LLY other info.
http://investorshangout.com/Eli-Lilly-And-Company-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Earnings Look Back: Eli Lilly Is Up 3.5% Since Reporting Quarterly Results 2 Weeks Ago (LLY)
Comtex SmarTrend(R) - 1 hr 20 mins ago
Two weeks ago on October 23rd, 2014 Eli Lilly (NYSE:LLY) reported earnings and analysts, on average, expected earnings of $0.67 on sales of $4.8 billion. The company actually reported EPS of $0.66 on sales of $4.9 billion, missing EPS estimates by $0.01 and beating revenue estimates by $37.8 million. Since the company's report, shares of Eli Lilly have risen from $64.35 to $66.60, representing a gain of 3.5% in the past 18 days.
LLY: 67.96 (+1.36)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 2 hrs 2 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.35 (+0.05), IMMU: 3.65 (+0.04), PCYC: 133.20 (-0.29), ONCY: 0.81 (+0.11), PFE: 30.20 (+0.28), LLY: 67.96 (+1.36), BMY: 58.54 (+0.22), GSK: 45.17 (+0.26), JNJ: 108.64 (+0.44), SNTA: 3.10 (-0.04), NVS: 92.43 (+0.67), XLRN: 31.63 (+1.44), ARRY: 3.87 (-0.01), CELGZ: 3.17 (-0.07), EXEL: 1.77 (+0.03)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 2 hrs 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.33 (+1.89), LLY: 67.96 (+1.36), CNCE: 13.61 (+0.51), OPK: 8.58 (+0.26), AZN: 73.31 (+0.43), ALXN: 194.09 (+0.28), ICPT: 178.82 (+6.23), NPSP: 26.85 (-0.64), XLRN: 31.63 (+1.44)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - 2 hrs 25 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.64 (+0.04), IMGN: 9.84 (+0.07), AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36), ONTX: 4.84 (+0.06), BMY: 58.54 (+0.22), GSK: 45.17 (+0.26), OXGN: 2.03 (-0.13), XLRN: 31.63 (+1.44), KPTI: 43.70 (+1.56), NVS: 92.43 (+0.67)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - 2 hrs 41 mins ago
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.96 (+1.36), ALKS: 52.72 (+1.72)
Lilly's Trulicity(TM) (dulaglutide) Now Available in U.S. Pharmacies
PR Newswire - Mon Nov 10, 9:00AM CST
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (NYSE: LLY) Trulicity(TM) (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle.
LLY: 67.96 (+1.36)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.96 (+1.36), GSK: 45.17 (+0.26), MNKD: 5.87 (+0.09), NVS: 92.43 (+0.67)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.68 (-0.02), MNK: 92.76 (+1.70), BAX: 70.53 (-0.08), LLY: 67.96 (+1.36)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 58.10 (+0.40), LLY: 67.96 (+1.36), ABBV: 63.53 (+2.03), GSK: 45.17 (+0.26), BMY: 58.54 (+0.22)
Technical Updates, Quarterly Earnings, Legislated Requirements, Lawsuit Dismissal, and Revised Operational Structure - Research Reports on United Rentals, Lilly, Quest Diagnostics, Agilent and GE
PR Newswire - Thu Nov 06, 7:40AM CST
Today, Analysts Review released its research reports regarding United Rentals, Inc. (NYSE: URI), Eli Lilly and Company (NYSE: LLY), Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A) and General Electric Company (NYSE: GE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7739-100free.
GE: 26.47 (+0.06), A: 41.12 (+0.19), DGX: 62.93 (+1.24), LLY: 67.96 (+1.36), URI: 113.88 (+0.49)
Human Insulin Market worth $42 Billion by 2019 - Prominent Players are Novo Nordisk (Denmark), Eli Lilly (U.S) & Biocon (India)
M2 - Thu Nov 06, 6:06AM CST
Human insulin for therapeutic use is a non-glycosylated, disulphide-bonded heterodimer of 51 amino acids and has a key role in regulating glucose metabolism. It is an important drug for treating diabetes mellitus, mainly type 1 diabetes. Both biologics (Branded drugs), and biosimilars (Generic version of branded drugs) have been covered in this study.
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 73.31 (+0.43), SPPI: 7.44 (+0.11), LLY: 67.96 (+1.36), GSK: 45.17 (+0.26), NVS: 92.43 (+0.67)
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.29 (-0.03), PFE: 30.20 (+0.28), AZN: 73.31 (+0.43), TTHI: 6.42 (-0.01), TEVA: 58.10 (+0.40), ITCI: 15.14 (-0.12), LLY: 67.96 (+1.36), OMER: 17.18 (-0.19)
Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy
PR Newswire - Wed Nov 05, 1:49PM CST
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. CYRAMZA now has two FDA approvals for these patients. Today's announcement follows the April approval of CYRAMZA as a single agent - the first approval of a treatment in the U.S. for patients in this setting.
LLY: 67.96 (+1.36)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.44 (+0.20), CRUS: 19.57 (+0.02), LLY: 67.96 (+1.36)
Cloud Pharmaceuticals Announces World-Class Board of Directors
PR Newswire - Wed Nov 05, 7:00AM CST
Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it ratified its board of directors at its annual meeting on September 16, 2014. Members of the board include Cloud Pharmaceuticals Chairman and CEO, Ed Addison, CSO Shahar Keinan, PhD, and CIO Lawrence Husick. Other members of the board include:
AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36)
China Recombinant & Modern Insulin Market 2014-2018
M2 - Wed Nov 05, 5:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kld485/insulin_market_in) has announced the addition of the "Insulin Market in China 2014-2018" report to their offering. The Insulin market in China to grow at a CAGR of 15.57% over the period 2013-2018 One key trend witnessed in the market is an increase in strategic alliances among vendors. There has been a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. According to the report, an increase in the number of patients suffering from diabetes and diabetes-related diseases is one of the major growth factors in this market. Over the last few years, almost 92 million people have been diagnosed with diabetes in China, and this is expected to increase to 435 million by 2030. Further, the report states that one of the main challenges in the market is the high cost of insulin. The average price of human insulin developed by the global vendors in China is higher than that of the human insulin developed by the regional or local vendors in the country. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products. Key Vendors - Eli Lilly - Novo Nordisk - Sanofi - Tonghua Dongbao Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type - Market Assessment of Top Drugs - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kl..._market_in
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
NeuroPhage Appoints Industry Veteran Franz Hefti, PhD, President/COO
PR Newswire - Tue Nov 04, 6:00AM CST
NeuroPhage Pharmaceuticals, Inc., a pioneering drug development company focused on diseases of protein misfolding, today announced the appointment of Dr. Franz Hefti, PhD, to President and Chief Operating Officer. Dr. Hefti has extensive experience in drug development for neurodegenerative diseases, recently serving as Chief Scientific Officer at Avid Radiopharmaceuticals, now a subsidiary of Eli Lilly, and formerly serving as the Executive Vice President of Drug Development at Rinat Neuroscience, which was acquired by Pfizer. His immediate focus will be to support the current clinical development programs focused on Alzheimer's and Parkinson's diseases, broaden the Company's therapeutic focus to include orphan disease indications, and enhance NeuroPhage's in-house development capabilities
LLY: 67.96 (+1.36)
Global Peptide Therapeutics Market 2014-2018: Key Vendors are AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi
PR Newswire - Mon Nov 03, 12:14PM CST
Research and Markets has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering.
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
Recent News posted below.
Eli Lilly and Company LLY other info.
http://investorshangout.com/Eli-Lilly-And-Company-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Earnings Look Back: Eli Lilly Is Up 3.5% Since Reporting Quarterly Results 2 Weeks Ago (LLY)
Comtex SmarTrend(R) - 1 hr 20 mins ago
Two weeks ago on October 23rd, 2014 Eli Lilly (NYSE:LLY) reported earnings and analysts, on average, expected earnings of $0.67 on sales of $4.8 billion. The company actually reported EPS of $0.66 on sales of $4.9 billion, missing EPS estimates by $0.01 and beating revenue estimates by $37.8 million. Since the company's report, shares of Eli Lilly have risen from $64.35 to $66.60, representing a gain of 3.5% in the past 18 days.
LLY: 67.96 (+1.36)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 2 hrs 2 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.35 (+0.05), IMMU: 3.65 (+0.04), PCYC: 133.20 (-0.29), ONCY: 0.81 (+0.11), PFE: 30.20 (+0.28), LLY: 67.96 (+1.36), BMY: 58.54 (+0.22), GSK: 45.17 (+0.26), JNJ: 108.64 (+0.44), SNTA: 3.10 (-0.04), NVS: 92.43 (+0.67), XLRN: 31.63 (+1.44), ARRY: 3.87 (-0.01), CELGZ: 3.17 (-0.07), EXEL: 1.77 (+0.03)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 2 hrs 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.33 (+1.89), LLY: 67.96 (+1.36), CNCE: 13.61 (+0.51), OPK: 8.58 (+0.26), AZN: 73.31 (+0.43), ALXN: 194.09 (+0.28), ICPT: 178.82 (+6.23), NPSP: 26.85 (-0.64), XLRN: 31.63 (+1.44)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - 2 hrs 25 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.64 (+0.04), IMGN: 9.84 (+0.07), AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36), ONTX: 4.84 (+0.06), BMY: 58.54 (+0.22), GSK: 45.17 (+0.26), OXGN: 2.03 (-0.13), XLRN: 31.63 (+1.44), KPTI: 43.70 (+1.56), NVS: 92.43 (+0.67)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - 2 hrs 41 mins ago
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.96 (+1.36), ALKS: 52.72 (+1.72)
Lilly's Trulicity(TM) (dulaglutide) Now Available in U.S. Pharmacies
PR Newswire - Mon Nov 10, 9:00AM CST
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (NYSE: LLY) Trulicity(TM) (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle.
LLY: 67.96 (+1.36)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.96 (+1.36), GSK: 45.17 (+0.26), MNKD: 5.87 (+0.09), NVS: 92.43 (+0.67)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.68 (-0.02), MNK: 92.76 (+1.70), BAX: 70.53 (-0.08), LLY: 67.96 (+1.36)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 58.10 (+0.40), LLY: 67.96 (+1.36), ABBV: 63.53 (+2.03), GSK: 45.17 (+0.26), BMY: 58.54 (+0.22)
Technical Updates, Quarterly Earnings, Legislated Requirements, Lawsuit Dismissal, and Revised Operational Structure - Research Reports on United Rentals, Lilly, Quest Diagnostics, Agilent and GE
PR Newswire - Thu Nov 06, 7:40AM CST
Today, Analysts Review released its research reports regarding United Rentals, Inc. (NYSE: URI), Eli Lilly and Company (NYSE: LLY), Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A) and General Electric Company (NYSE: GE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7739-100free.
GE: 26.47 (+0.06), A: 41.12 (+0.19), DGX: 62.93 (+1.24), LLY: 67.96 (+1.36), URI: 113.88 (+0.49)
Human Insulin Market worth $42 Billion by 2019 - Prominent Players are Novo Nordisk (Denmark), Eli Lilly (U.S) & Biocon (India)
M2 - Thu Nov 06, 6:06AM CST
Human insulin for therapeutic use is a non-glycosylated, disulphide-bonded heterodimer of 51 amino acids and has a key role in regulating glucose metabolism. It is an important drug for treating diabetes mellitus, mainly type 1 diabetes. Both biologics (Branded drugs), and biosimilars (Generic version of branded drugs) have been covered in this study.
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 73.31 (+0.43), SPPI: 7.44 (+0.11), LLY: 67.96 (+1.36), GSK: 45.17 (+0.26), NVS: 92.43 (+0.67)
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.29 (-0.03), PFE: 30.20 (+0.28), AZN: 73.31 (+0.43), TTHI: 6.42 (-0.01), TEVA: 58.10 (+0.40), ITCI: 15.14 (-0.12), LLY: 67.96 (+1.36), OMER: 17.18 (-0.19)
Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy
PR Newswire - Wed Nov 05, 1:49PM CST
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. CYRAMZA now has two FDA approvals for these patients. Today's announcement follows the April approval of CYRAMZA as a single agent - the first approval of a treatment in the U.S. for patients in this setting.
LLY: 67.96 (+1.36)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.44 (+0.20), CRUS: 19.57 (+0.02), LLY: 67.96 (+1.36)
Cloud Pharmaceuticals Announces World-Class Board of Directors
PR Newswire - Wed Nov 05, 7:00AM CST
Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it ratified its board of directors at its annual meeting on September 16, 2014. Members of the board include Cloud Pharmaceuticals Chairman and CEO, Ed Addison, CSO Shahar Keinan, PhD, and CIO Lawrence Husick. Other members of the board include:
AMGN: 162.14 (+1.89), LLY: 67.96 (+1.36)
China Recombinant & Modern Insulin Market 2014-2018
M2 - Wed Nov 05, 5:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kld485/insulin_market_in) has announced the addition of the "Insulin Market in China 2014-2018" report to their offering. The Insulin market in China to grow at a CAGR of 15.57% over the period 2013-2018 One key trend witnessed in the market is an increase in strategic alliances among vendors. There has been a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. According to the report, an increase in the number of patients suffering from diabetes and diabetes-related diseases is one of the major growth factors in this market. Over the last few years, almost 92 million people have been diagnosed with diabetes in China, and this is expected to increase to 435 million by 2030. Further, the report states that one of the main challenges in the market is the high cost of insulin. The average price of human insulin developed by the global vendors in China is higher than that of the human insulin developed by the regional or local vendors in the country. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products. Key Vendors - Eli Lilly - Novo Nordisk - Sanofi - Tonghua Dongbao Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type - Market Assessment of Top Drugs - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kl..._market_in
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
NeuroPhage Appoints Industry Veteran Franz Hefti, PhD, President/COO
PR Newswire - Tue Nov 04, 6:00AM CST
NeuroPhage Pharmaceuticals, Inc., a pioneering drug development company focused on diseases of protein misfolding, today announced the appointment of Dr. Franz Hefti, PhD, to President and Chief Operating Officer. Dr. Hefti has extensive experience in drug development for neurodegenerative diseases, recently serving as Chief Scientific Officer at Avid Radiopharmaceuticals, now a subsidiary of Eli Lilly, and formerly serving as the Executive Vice President of Drug Development at Rinat Neuroscience, which was acquired by Pfizer. His immediate focus will be to support the current clinical development programs focused on Alzheimer's and Parkinson's diseases, broaden the Company's therapeutic focus to include orphan disease indications, and enhance NeuroPhage's in-house development capabilities
LLY: 67.96 (+1.36)
Global Peptide Therapeutics Market 2014-2018: Key Vendors are AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi
PR Newswire - Mon Nov 03, 12:14PM CST
Research and Markets has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering.
NVO: 43.39 (-0.30), LLY: 67.96 (+1.36)
(0)
(0)Eli Lilly & Co. (LLY) Stock Research Links
Scroll down for more posts ▼